Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.
Source: MarketWatch
Thursday, 04. December 2025
Share:
03. December 2025 20:05
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
